Eshaghi, Behnaz
Schudel, Alex
Sadeghi, Ilin
Chen, Ziqi http://orcid.org/0000-0002-3512-1190
Lee, Amy H.
Kanelli, Maria http://orcid.org/0000-0002-0031-8866
Tierney, Flora
Han, Jooli
Ingalls, Bailey
Francis, David M.
Li, Gary
von Andrian, Ulrich
Langer, Robert http://orcid.org/0000-0003-4255-0492
Jaklenec, Ana http://orcid.org/0000-0001-6096-0538
Article History
Accepted: 10 November 2023
First Online: 18 December 2023
Competing interests
: R.L. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities: 611 Therapeutics; Abpro International; Acorda (formerly Civitas Therapeutics); Alfred University; Aleph Farms; Alivio Therapeutics; Alkermes; Allevi; Allurion; Alnylam Pharmaceuticals, Inc; Amberstone Bioscience; Amgen; aMoon; Apotex; Arcadia Biosciences, Inc; Arsenal Medical; Artificial Cell Technology, Inc; Avalon-Globocare; Bai Biosciences; BASF Corporation; Bayer; Balzan Foundation; Bexson Biomedical; Bilayer Therapeutics; Biogen; BioInnovation Institute (Novo Nordisk Founden); BioTE Medical; Blackrock; Blackstone (formerly Clarus); Boston Children’s Hospital; CBC Group Investment Mgmt Group; Celanese; Celero; Cellink/BICO; Cellomics Technology LLC; Cellular Biomedical; CE&N/ACS; Charles River Laboratories, Inc.; Clontech Laboratories; Combined Therapeutics (CTx); Conference Forum; Cornell University; Crispr Therapeutics Ag; Crown Bioscience, Inc.; Daré Biosciences (formerly Microchips Biotech, Juniper Pharmaceuticals and Columbia Laboratories); Daros, Inc.; DeepBiome; Dewpoint Therapeutics; Dispendix; Eagle Pharmaceuticals; Earli; Edigene Biotechnology, Inc.; Editas Medicine, Inc.; ELC (Estee Lauder Companies); Eli Lilly; Eisai, Inc.; Entrega; EpiBone; Establishment Labs, SA.; Everlywell; Evox Therapeutics, Ltd.; Fate; Flagship Pioneering; Frequency Therapeutics, Inc.; GeneLeap Biotech; Genemedicine Co Lmtd; GenScript USA, Inc; Geneo Medicine; GENUV; Glaxosmithkline LLC; Glycobia; Glympse Bio; Goldman Sachs; Greenlight Biosciences; HCR (HealthCare Royalty Partners); HKF DNA Technologies; Hopewell Therapeutics; Horizon Discovery Group Plc; Humacyte, Inc.; IBEX Pharmaceuticals, Inc.; Immunai; ImmuneXcite, Inc.; Institute of Immunology Co. Ltd; Integrated DNA Technologies, Inc.; InVivo Therapeutics; IxBio; J.R. Simplot Company; Jnana Therapeutics; Kala Pharmaceuticals; Kallyope, Inc.; Kendall Capital; Kensa; Kodikaz Therapeutics; KAST (Korean Academy of Science and Technology); Ksq Therapeutics, Inc.; Kunlun Capital; Landsdowne Labs; LikeMinds; Lonza; Luminopia, Inc.; Luye (Shandong luye); Lyndra Therapeutics; Lyra Therapeutics (formerly 480 Biomedical); Maurice Marie Janot Award 2020; McGovern Institute; Medikinetics Co., Ltd.; Merck; MGH Ragon Institute; Micelle; Moderna Therapeutics; Momenta; Muse Biotechnologies, Inc.; Mylan; N2Tech; Nanobiosym; Nanobiotix; Neochromosone; Neoteny 4 LLP; NextRNA; Newbridge Ventures LLC; Noveome Biotherapeutics, Inc.; Novo Nordisk; Ohio State University; Olivo (acquired by Shiseido); Ovid Therapeutics; Particles for Humanity; Pfizer, Inc.; Pioneer Hi-Bred International, Inc.; Placon Therapeutics; Polaris Partners; Pontifical Academy of Sciences; Portal Instruments; Preceres LLC (acquired by Monsanto); PrognomIQ, Inc.; Pulmatrix; PureTech; Quris; ReLive; Rensselaer Polytechnic Institute/Department of Chemical and Biological Engineering; Reprocell USA, Inc. (formerly Stemgent); Replay Bio; Rubius Therapeutics; Satellite Bio; SBEF (Seoul Bio Economy Forum); Secant Medical, Inc.; Seer, Inc.; Selecta Biosciences; Senses LLC; Setsuro Tech Inc.; Seventh Sense Biosystems, Inc.; Shenzhen Rice Life Technology, Ltd; Shire Ag; Sigilon; Sigma Aldrich Co. LLC; SiO2 Materials Science; Ske S.R.L.; Soil Culture Solutions LLC (Dba Soilcea); Souffle Therapeutics; SQZ Biotechnologies; StemBioSys, Inc.; SuonoBio; T2 Biosystems; Taconic Biosciences, Inc. (formerly Taconic Farms); Taiwania Capital (Bio-Asia Taiwan Symposium); TARA; Tarveda Therapeutics; Teal Bio; Terasaki Institute; Tesio Pharmaceuticals; Third Rock Ventures; Tiba Biotech LLC; TissiuM (formerly Gecko); Transgenic, Inc.; Translate Bio (formerly Rana Therapeutics, Inc.); Trilink Biotechnologies, Inc.; Unilever (Living Proof); University of Bergen, Norway (Falch Lecture Honorarium); VasoRX; Verseau Therapeutics, Inc.; Virex Health; Vitakey; Vivtex Corporation; Westlake University; Whitehead Institute; Wiki Foods; Xenter; YourBio (formerly 7th Sense Biosystems); Yz Biosciences (Guangzhou), Inc.; Zenomics; ZWI Therapeutics. A.J. receives licensing fees (to patents on which she was an inventor) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which she was not paid for the following entities: Moderna Therapeutics; OmniPulse Biosciences; Particles for Humanity; SiO2 Materials Science; Takeda (formerly Shire Ag); VitaKey. All the other authors declare no competing interests.